Immuneel Therapeutics, an integrated cell and gene therapy platform founded by Biocon founder Kiran Mazumdar-Shaw, has raised over Rs 100 crore in a Series B round of funding with participation from Singularity AMC, Rainmatter by Zerodha, and high networth individuals.
This funding round also saw participation of existing investors, Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
Immuneel Therapeutics will use this funding round to scale its GMP manufacturing capacity, advance its next-generation deep-tech cell and gene therapy pipeline toward clinical milestones, support the commercialisation of Qartemi, and accelerate international market entry across Asia Pacific and Middle East.
Founded in 2018 and headquartered in Bengaluru, Immuneel Therapeutics is a clinical-stage biotech company, it has commercially launched Qartemi, an approved CAR-T therapy.
It also has global co-development partnerships in Australia and Southeast Asia.
